53 institutions hold shares in Avenue Therapeutics Inc. (ATXI), with 10.1M shares held by insiders accounting for 60.29% while institutional investors hold 31.06% of the company’s shares. The shares outstanding are 16.56M, and float is at 6.65M with Short Float at 6.05%. Institutions hold 12.33% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.94 million shares valued at $5.59 million. The investor’s holdings represent 5.61% of the ATXI Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 0.36 million shares valued at $2.15 million to account for 2.16% of the shares outstanding. The other top investors are National Asset Management, Inc. which holds 0.17 million shares representing 1.00% and valued at over $1.0 million, while Geode Capital Management, LLC holds 0.75% of the shares totaling 0.13 million with a market value of $0.75 million.
Avenue Therapeutics Inc. (NASDAQ: ATXI) is 1.68% higher on its value in year-to-date trading and has touched a low of $2.85 and a high of $12.34 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ATXI stock was last observed hovering at around $6.62 in the last trading session, with the day’s loss setting it -0.57% off its average median price target of $6.00 for the next 12 months. It is also -0.83% off the consensus price target high of $6.00 offered by 1 analysts, but current levels are -0.83% lower than the price target low of $6.00 for the same period.
Currently trading at $6.05, the stock is -2.36% and -0.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.57 million and changing -8.61% at the moment leaves the stock -17.89% off its SMA200. ATXI registered -31.95% loss for a year compared to 6-month loss of -44.80%. The firm has a 50-day simple moving average (SMA 50) of $5.87 and a 200-day simple moving average (SMA200) of $5.75.
The stock witnessed a 0.00% gain in the last 1 month and extending the period to 3 months gives it a 1.34%, and is 6.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.03% over the week and 7.67% over the month.
Fwd P/E is 10.17. Distance from 52-week low is 112.28% and -50.97% from its 52-week high.
Avenue Therapeutics Inc. (ATXI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Avenue Therapeutics Inc. (ATXI) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Avenue Therapeutics Inc. is expected to release its quarterly report on 08/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06.The EPS is expected to grow by 81.10% this year
Avenue Therapeutics Inc. (ATXI) Insider Activity
A total of 0 insider transactions have happened at Avenue Therapeutics Inc. (ATXI) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Vazzano Joseph Walter, the company’s Chief Financial Officer. SEC filings show that Vazzano Joseph Walter sold 3,840 shares of the company’s common stock on Aug 20 at a price of $12.13 per share for a total of $46579.0. Following the sale, the insider now owns 57412.0 shares.
Avenue Therapeutics Inc. (ATXI): Who are the competitors?
Omeros Corporation (OMER) is 45.92% up on the 1-year trading charts. Short interest in the company’s stock has risen 4.71% from the last report on Feb 11, 2021 to stand at a total of 0.38 million short shares sold with a short interest ratio of 1.7.